Viral reactivations following hematopoietic stem cell transplantation in pediatric patients – A single center 11-year analysis release_zhqnki6zmrdovhhcuswtxp6o3y

by Franziska Düver, Benedikt Weißbrich, Matthias Eyrich, Matthias Wölfl, Paul G. Schlegel, Verena Wiegering

Published in PLoS ONE by Public Library of Science (PLoS).

2020   Volume 15, Issue 2, e0228451


Viral reactivation occurs frequently in the context of immunodeficiency and immunosuppression after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and can cause severe complications. The aim of this single-center retrospective analysis was to characterize viral infections in the first year after HSCT, to investigate risk factors and to study the impact of viral infections on transplantation outcome. This will facilitate the identification of at-risk patients and the development of new preventive strategies. 107 pediatric allo-HSCT from January 2005 through December 2015 were analyzed for infections with Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus 6 (HHV-6), adenovirus (ADV), herpes simplex virus (HSV) and varicella zoster virus (VZV). Viral infections were detected after 68.2% of transplantations. The viruses most commonly encountered were HHV-6 (36/107) and EBV (30/107). Severe viral disease was rare (7/107) and none of the patients died as result of viral reactivation. Important risk factors for viral infections were higher age at HSCT, donor type and occurrence of acute graft-versus-host disease (aGvHD). Especially for EBV, transplant from an unrelated donor and in-vivo T-cell depletion (TCD) had a significant effect on infection rates, whereas for CMV the strongest effect was seen by donor and recipient serostatus with recipient seropositivity most predictive for reactivation. The occurrence of severe aGvHD was associated with EBV and ADV infections. For HSV, the recipient serostatus was identified as prognostic factor for HSV infections, while we found higher age at time of HSCT as risk factor for VZV infections. The overall survival of patients with or without viral infections did not differ significantly. Interestingly, when looking at the 85 patients in our cohort who had received an HSCT for a malignant disease, a tendency towards lower relapse rates was seen in patients affected by viral infections (HR 0.51, 95% CI 0.25 - 1.06, p = 0.072). Viral reactivations are common after pediatric allo-HSCT, though severe complications were rare in our collective. Determining risk factors for viral reactivations may help to identify patients in need of intensified monitoring and to individualize preventive strategies.
In text/plain format

Archived Files and Locations

application/pdf  672.5 kB
file_b4rmbvkdgbd2va2ujsmkzpd7ku (webarchive) (publisher)
Read Archived PDF
Type  article-journal
Stage   published
Date   2020-02-04
Language   en ?
Container Metadata
Open Access Publication
Not in Keepers Registry
ISSN-L:  1932-6203
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 29afbb01-d78d-47be-b870-8bec2465e268